awmsg logo



adalimumab (Humira®)


Reference No. 3035

Publication date:
12/12/2017


Appraisal information

adalimumab (Humira®) 40 mg solution for injection


Company: AbbVie Ltd
BNF category: Eye
NMG meeting date: 01/11/2017
AWMSG meeting date: 06/12/2017
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2717
Ratification by Welsh Government: 08/12/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of paediatric chronic non-infectious anterior uveitis in patients from two years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download